[{"address1": "4464 Markham Street", "address2": "Suite 1203", "city": "Victoria", "state": "BC", "zip": "V8Z 7X8", "country": "Canada", "phone": "250 708 4272", "website": "https://www.auriniapharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.", "fullTimeEmployees": 300, "companyOfficers": [{"maxAge": 1, "name": "Mr. Peter S. Greenleaf M.B.A.", "age": 53, "title": "President, CEO & Director", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": 1335386, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joseph M. Miller CPA", "age": 49, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2022, "totalPay": 791921, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew Maxwell Donley M.B.A.", "age": 54, "title": "Executive Vice President of Operations & Strategy", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": 811824, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen P. Robertson", "age": 41, "title": "Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer", "yearBorn": 1982, "fiscalYear": 2022, "totalPay": 739682, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Volker  Knappertz D.Sc., M.D.", "age": 58, "title": "Executive Vice President of Research & Development", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": 742847, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James Archie Harrell Jr.", "age": 53, "title": "Head of Investor Relations", "yearBorn": 1970, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Fran  Lynch", "title": "Vice President of Sales", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael R. Martin", "age": 51, "title": "Chief Business Officer", "yearBorn": 1972, "fiscalYear": 2022, "totalPay": 350570, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sue  Evans", "title": "Senior Vice President of Global Regulatory Affairs", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Scott  Habig", "age": 63, "title": "Chief Commercial Officer", "yearBorn": 1960, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 5, "compensationRisk": 10, "shareHolderRightsRisk": 2, "overallRisk": 6, "governanceEpochDate": 1706745600, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 7.97, "open": 6.0, "dayLow": 5.5, "dayHigh": 6.19, "regularMarketPreviousClose": 7.97, "regularMarketOpen": 6.0, "regularMarketDayLow": 5.5, "regularMarketDayHigh": 6.19, "beta": 1.459, "forwardPE": -17.705883, "volume": 19560733, "regularMarketVolume": 19560733, "averageVolume": 2177303, "averageVolume10days": 1802850, "averageDailyVolume10Day": 1802850, "bidSize": 1000, "askSize": 4000, "marketCap": 870600384, "fiftyTwoWeekLow": 5.5, "fiftyTwoWeekHigh": 12.43, "priceToSalesTrailing12Months": 5.480541, "fiftyDayAverage": 8.4332, "twoHundredDayAverage": 9.1224, "currency": "USD", "enterpriseValue": 900711040, "profitMargins": -0.48593, "floatShares": 140724512, "sharesOutstanding": 144618000, "sharesShort": 18529600, "sharesShortPriorMonth": 15569034, "sharesShortPreviousMonthDate": 1703808000, "dateShortInterest": 1706659200, "sharesPercentSharesOut": 0.129, "heldPercentInsiders": 0.072129995, "heldPercentInstitutions": 0.38674998, "shortRatio": 8.4, "shortPercentOfFloat": 0.1295, "impliedSharesOutstanding": 143608000, "bookValue": 2.729, "priceToBook": 2.2059362, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -77191000, "trailingEps": -0.54, "forwardEps": -0.34, "enterpriseToRevenue": 5.67, "enterpriseToEbitda": -10.826, "52WeekChange": -0.026862025, "SandP52WeekChange": 0.22591555, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "AUPH", "underlyingSymbol": "AUPH", "shortName": "Aurinia Pharmaceuticals Inc", "longName": "Aurinia Pharmaceuticals Inc.", "firstTradeDateEpochUtc": 1409751000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "6af70c53-6225-3411-b004-ce20a00fb8bf", "messageBoardId": "finmb_882669", "gmtOffSetMilliseconds": -18000000, "currentPrice": 6.02, "targetHighPrice": 15.0, "targetLowPrice": 9.5, "targetMeanPrice": 13.21, "targetMedianPrice": 13.0, "recommendationMean": 2.1, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 337060000, "totalCashPerShare": 2.347, "ebitda": -83200000, "totalDebt": 93214000, "quickRatio": 5.075, "currentRatio": 5.772, "totalRevenue": 158852992, "debtToEquity": 23.787, "revenuePerShare": 1.112, "returnOnAssets": -0.10797, "returnOnEquity": -0.18936001, "freeCashflow": 2425250, "operatingCashflow": -37323000, "revenueGrowth": -0.023, "grossMargins": 0.6396, "ebitdaMargins": -0.52375, "operatingMargins": -0.29832, "financialCurrency": "USD", "trailingPegRatio": null}]